Specify a stock or a cryptocurrency in the search bar to get a summary
Adicet Bio Inc
ACETAdicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts. Address: 200 Clarendon Street, Boston, MA, United States, 02116
Analytics
WallStreet Target Price
15.67 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ACET
Dividend Analytics ACET
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
15 %Dividend History ACET
Stock Valuation ACET
Financials ACET
Results | 2019 | Dynamics |